Market news

BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16 in New York City, NY. On-demand Company Presentation Date and Time:

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. “The second quarter marked an important period of execution for Gain, highlighted by FDA authorization of our IND for rexaceract, which posit

Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...